Support for Yale Cancer Answers comes from AstraZeneca, dedicated to providing innovative treatment options for people living with cancer. Learn more at astrazeneca-us.com.

Welcome to Yale Cancer Answers with your host doctor Anees Chagpar.

Yale Cancer Answers features the latest information on cancer care by welcoming oncologists and specialists who are on the forefront of the battle to fight cancer. This week it’s a conversation about pancreatic cancer with Doctor Jeremy Kortmansky.

Doctor Kortmansky is an associate professor of clinical medicine in medical oncology at the Yale School of Medicine where Doctor Chagpar is a professor of surgical oncology.

So Jeremy, I think we all hear about pancreatic cancer when it affects celebrities, right? So whether it was Steve Jobs or other stars we hear about pancreatic cancer, once in a blue moon. It doesn’t seem to be a terribly common cancer.

Can you tell us a little bit more about how frequently
pancreatic cancer is diagnosed?
How many people get it?
And who really are the people that it most affects?
Yes, pancreatic cancer is actually becoming an increasingly more common cancer that we see.
It’s now the 5th leading cause of cancer in the United States, at about 60,000 new cases a year. So we’re not only seeing increasing numbers, but also really moving up the rank of how often we see it.
And you know it’s interesting you brought up Steve Jobs and other celebrities. Most recently, I think Alex Trebek is one and it’s important to make distinctions when we talk about pancreatic cancer, there’s two main types there: pancreatic adenocarcinoma, which is by far the more common one that is the disease that we’re talking about. when we think about 60,000 cases per year. And then there are pancreatic neuroendocrine tumors, which are a lot less common. They are only seen in a few thousand patients a year, and it’s important to make the distinction because
they behave very differently and their treatments are very different. So, let’s start with pancreatic adenocarcinoma, because I think that most people, when they use the term generically pancreatic cancer that tends to be what they’re referring to. Although your point is well taken with regards to neuroendocrine tumors, but tell us a little bit more about who gets these cancers. I mean, what are the risk factors? So I think like other cancers, smoking is a common risk factor. I mean, what are the risk factors? I think like other cancers, smoking is a common risk factor. It can be related to problems that cause chronic inflammation of the pancreas so alcoholism can lead to pancreas cancer. Chronic gallstone disease can, although that’s much less common. Obesity can be a risk factor as well. And then there is some question of the relationship with diabetes and whether diabetes could be a risk factor or whether the disease itself causes the diabetes. And that’s something that’s still being worked out. And then there is a smaller percentage of patients where it’s hereditary cancer. There are some genetic abnormalities
that we know of that are associated with pancreas cancer and one that is of recent importance is its relation to the BRCA gene, which is a gene that we most often think about with breast and ovarian cancer syndromes, but is also related to pancreas cancer as well, and that has had some recent implications on treatment. So when we think about these risk factors, I’m thinking about a very good friend of mine who actually was diagnosed with pancreatic cancer just over Thanksgiving. And who didn’t fit any of those categories. She had no family history. She is skinny, like a rail, she doesn’t have diabetes, doesn’t drink, doesn’t have gallstones. You know, in those people where they don’t seem to have any of the common risk factors that you think about for pancreatic cancer, does that tell us anything about the biology of their disease? I mean, are there other things that we can think of in terms of their risk factors, and does that
0:05:18.108 –> 0:05:20.46 have anything to do with their prognosis?
0:05:20.549 –> 0:05:22.637 I think that those are all very good questions.
0:05:23.99 –> 0:05:26.165 There are risk factors that we can identify and then there are patients who get cancer for really no good reason.
0:05:27.91 –> 0:05:30.22 And those are people that we are still trying to maybe figure out whether there was something hereditary or environmental or some other factor that we just haven’t identified yet that played a role.
0:05:38.38 –> 0:06:05.18 When it comes to pancreas cancer, except in in certain circumstances, like the BRCA gene but, otherwise how you got it doesn’t play as much of a role into how we might think about treating it or how we might expect it to behave.
0:06:06.96 –> 0:06:08.74 So the the other question is, when you talk about it being the fifth most common cancer and we think about the list right?
0:06:14.633 –> 0:06:16.791 breast cancer, prostate cancer, colon cancer for all of these, more commonly diagnosed cancers, there’s a screening test we can find these cancers early.
Is there a screening test for pancreatic cancer?

There isn’t a good or routine screening test for pancreas cancer.

I think that we know that there are some patients that have been discovered to have either a family history or patients that have been found to have pancreatic cysts on their imaging that may have been obtained for some other reason that we can follow and certainly here at Yale, we have an excellent screening program where we can refer patients to our gastroenterologists who can perform screening procedures, but that’s really identifying those who are already at a heightened risk and not for the whole population like we think about with colonoscopies for colon cancer or mammograms for breast cancer.

It’s really an already pre determined population because the screening includes much more advanced or invasive testing like MRI’s or endoscopic ultrasound.

So it’s a much more complex way to follow patients.

And so without a screening test for asymptomatic people who otherwise, haven’t had any
0:08:13.825 –> 0:08:15.925 abnormality that’s been found
0:08:15.93 –> 0:08:17.646 incidentally, what are
0:08:17.646 –> 0:08:20.765 the ways in
0:08:20.765 –> 0:08:23.135 which they present?
0:08:23.135 –> 0:08:25.48 how is it that somebody
0:08:25.549 –> 0:08:28.198 cues into the fact that, Oh my gosh,
0:08:28.198 –> 0:08:30.214 this could be a pancreatic cancer.
0:08:30.22 –> 0:08:33.244 What are the symptoms and signs to look for?
0:08:34.6 –> 0:08:38.08 I again think this is an area
0:08:38.08 –> 0:08:40.379 that becomes challenging that
0:08:40.379 –> 0:08:43.699 the symptoms that people have,
0:08:43.7 –> 0:08:47.438 at least initially can often be vague.
0:08:47.44 –> 0:08:50.115 There can be some discomfort
0:08:50.115 –> 0:08:52.792 in the abdomen, with eating,
0:08:52.792 –> 0:08:54.4 sometimes increased belching,
0:08:54.4 –> 0:08:58.138 or increased gas may be a symptom.
0:08:58.14 –> 0:09:00.755 Things that are very easily
0:09:00.755 –> 0:09:03.37 attributable to something else until
0:09:03.461 –> 0:09:06.486 the symptoms become more significant.
0:09:06.49 –> 0:09:08.466 Sometimes people present without
0:09:08.466 –> 0:09:10.936 any symptoms but develop jaundice,
0:09:10.936 –> 0:09:13.478 they notice yellowing
0:09:13.478 –> 0:09:15.88 of their eyes or their skin,
0:09:15.88 –> 0:09:18.11 which certainly tips them off,
0:09:18.11 –> 0:09:20.2 their families that there’s something
0:09:20.2 –> 0:09:23.03 going on that requires further evaluation.
0:09:23.03 –> 0:09:24.818 But because these symptoms
0:09:24.818 –> 0:09:26.606 can sometimes be vague,
0:09:26.61 –> 0:09:29.557 they can also be attributed to the
0:09:29.557 –> 0:09:32.753 much more common problems that we see,
0:09:32.753 –> 0:09:35.525 irritable bowel or reflux which can
lead to delays in making a diagnosis. And so I mean that really gets to the crux of the issue, right? Is that without screening and with the symptoms that are incredibly vague, I would surmise that the vast majority of patients who present with pancreatic cancer present at a more advanced stage so talk about the stage distribution that you see in terms of the proportion of patients who present with early versus late stage disease and what the implications are in terms of prognosis. People often think about staging for cancer with the usual stage one, two, three or four. When I think about pancreas cancer, I really try to think about it in terms of its clinical presentations and so there are patients that have resectable disease, meaning that a surgeon could go in there at the time of diagnosis and take it out. There are patients that have locally advanced but unresectable disease, meaning that it hasn’t spread to other parts of the body, but it’s involving the nearby blood vessels, and you can’t safely take it out.
And then patients with metastatic disease where it’s spread to other places in the body.
And so the number or the percentage of patients that can have surgery at the time of their diagnosis is really only about 15 to 20%. It’s a relatively low number and the other 80% sort of evenly distributed are either locally advanced or metastatic disease at the time of their diagnosis.
And so it was with my my friend who was diagnosed with a locally advanced, unresectable pancreatic cancer that was encasing important blood vessels, so she certainly wasn’t a candidate for surgery at the time of her presentation, so it sounds like if patients are fortunate enough to be resectable at the time of their presentation, would surgery be the primary modality upfront? That is a great question, and one that we are still trying to figure out. I think that there is clearly a standard paradigm of doing surgery followed by chemotherapy for about six months afterwards.
There is a lot of interest in giving chemotherapy prior to surgery or giving part of the chemotherapy, then surgery, and then chemotherapy after. And in fact, here at Smilow we have a clinical trial which is really looking at that question of perioperative chemotherapy. How do patients do getting some of the chemotherapy treatments before surgery, and then some after? And how that might compare to those who get surgery first and then chemotherapy later? And how effective is the chemotherapy? Because, I can imagine that many of the people who are listening to this show are thinking, if I have a cancer and you can take this cancer out and you can get it out of my body, for many people the simple logic is that might be better than having a chemotherapy, which may or may not work and they often have some trepidation about cancer spreading and then making it unresectable. So how effective is chemotherapy that we could potentially use it in a neoadjuvant fashion to potentially
even shrink the cancer and get some systemic control prior to resecting it?
So our newer chemotherapy regiments are good, they’re not great,
but they are good and they can shrink the disease for some and control the microscopic disease that might be floating around for others.
I think that the challenge ultimately is that even with surgery,
the risk of pancreatic cancer coming back because it has already shed these microscopic cells is very high,
and so by giving chemotherapy we are hopefully attacking some of those microscopic cells that are floating around,
but also making sure that putting somebody through what would be a very major operation is ultimately the right thing to do.
So many complicating moving parts in the management of pancreatic cancer and we’re going to learn much more about all of that right after we take a short break for a medical minute.
Please stay tuned to learn more about pancreatic cancer with my guest Doctor Jeremy Kortmansky.
Support for Yale Cancer Answers comes from AstraZeneca providing important treatment options
for various types and stages of cancer.

More information at astrazeneca-us.com.

This is a medical minute about head and neck cancers, although the percentage of oral and head and neck cancer patients in the United States is only about 5% of all diagnosed cancers, there are challenging side effects associated with these types of cancer and their treatment.

Clinical trials are currently underway to test innovative new treatments for head and neck cancers, and in many cases less radical surgeries are able to preserve nerves, arteries and muscles in the neck. Enabling patients to move, speak, breathe, and eat normally after surgery.

More information is available at yalecancercenter.org.

You’re listening to Connecticut Public Radio.

Welcome back to Yale Cancer Answers.

This is doctor Anees Chagpar and I am joined tonight by my guest doctor Jeremy Kortmansky.

We’re talking about pancreatic cancer and Jeremy right before the break, you had indicated to us that you really think about pancreatic cancer in terms of staging,
as whether things are resectable at the time of presentation or unresectable, but not metastatic or metastatic and sadly, 80% of patients or so fall into the last two buckets. And you know, that’s really unfortunate, because what is the prognosis for patients who have locally advanced unresectable disease at presentation? And what is the prognosis for patients who present with metastatic disease? For those patients who have advanced disease, unfortunately we view those as incurable cancers. We can’t make it go away and never come back. For patients that have locally advanced disease on occasion and it’s not the expectation, but on occasion they have a great response to the chemotherapy and we can revisit that question of surgery but without surgery, ultimately, patients succumb to their disease and the goals of our treatment are to control the disease for as long as possible. Help people live as long as possible and feel as well as possible knowing that the disease can be symptomatic as well.
For people who are listening to this and who may have had friends or even seen celebrities go through their own journeys with pancreatic cancer, when we say the goal is really to try to control the cancer for as long as possible and the quality of life for as long as possible, in some cancers we’ve discussed on this show, medical management has come a really long way such that even in those settings, people live for a long time and they talk about this being incurable, but really making it more of a chronic disease then something that is imminently fatal. Where are we in the spectrum of pancreatic cancer towards getting to oK, so I’ve got pancreatic cancer and I know that I can’t get rid of it, but I can live with it versus this is something that is more of an imminent concern. It’s still a very challenging disease and there are for a lot of other cancers, a lot of exciting new therapies and immunotherapy’s
for pancreas cancer, the majority of patients are still treated with versions of chemotherapy and those chemotherapy drugs are modest. There are some who are exceptional responders. People who do really well for a long time, but for the majority of patients, the survival is still only measured in in months or years. And doing better and finding better therapies is of such great importance for this disease. I think we are really hoping and trying every day to find therapies that are better than what we have currently. Do we have any factors that can predict who is going to respond better to chemotherapy versus not? I had mentioned this earlier, patients that have a BRCA mutation or a similar type mutation, we find that they are more sensitive to platinum based chemotherapy. So a drug like oxaliplatin or cisplatin. And that we can see better responses there that can sometimes last longer than we might see with a patient who
doesn’t have one of those abnormalities. We know that there is a class of PARP inhibitors, which for this mutated population can benefit from this targeted therapy. At the end of the day, that only makes up about 7% of the patients that we see. So it’s still not a not a big number and we know about 1% have another abnormality, called microsatellite instability, for which immunotherapy drugs have been helpful. And so we always test for that. But again, it’s one out of 100 that we see. The majority of the patients that we take care of are still treated similarly with these more generic chemotherapy programs with a strong emphasis in trying to encourage patients to participate in clinical trials that can help us move the field. And I want to get into the clinical trials in a minute. But before we get there, if you’re treated with standard chemotherapy and all of the side effects that go along with that, knowing that you’re presented with a locally advanced, unresectable or metastatic cancer, what is really the efficacy
of these chemotherapies?
I mean, how do patients balance the risk and the benefit of the therapy? Is this something that for some patients the therapy is worse than the disease itself? Or are these actually things that are tolerable with more modern day treatments and additional factors that you can give patients? And that has really been shown to make a difference in terms of both survival and quality of life. My job is to make the treatments tolerable. When we pick a regimen, there are two common regiments that we use. We are already thinking about what are the side effects that are associated with those regimens and whether the patient who's about to receive it is going to be able to tolerate it based on their age and other medical problems that they may have and when we give the treatments, we do so very carefully and we pay attention to those side effects to make adjustments in the dosing or give supportive medications to really make it as tolerable as we can.
It’s never a desired situation that the treatment is worse than the disease. And the reality is, that for the vast majority of patients when they do start feeling poorly, it’s more often the disease than it is the treatments. But we make sure we see patients every time before they get their treatments to review the side effects and give the right medications and supportive medications or dose adjustments that we need to do.

And how do we know that the chemotherapies are working? Many patients ask about well are you going to do more blood work? Are there tumor markers? Because you had mentioned that for some patients who present without metastatic disease, potentially in some of those patients, you can reassess whether they may be candidates for resection. The best way to follow the disease is with imaging so usually a CAT scan. Sometimes an MRI or a PET scan, but usually a CAT scan gives us the level of detail that we need,
0:25:13.65 -> 0:25:15.158 including the relationship of
0:25:15.158 -> 0:25:17.42 the tumor to the vessels nearby.
0:25:17.42 -> 0:25:19.922 For those who have locally advanced
0:25:19.922 -> 0:25:22.317 disease and there is a tumor
0:25:22.317 -> 0:25:24.578 marker that we can use as well,
0:25:27.38 -> 0:25:29.2 that can be helpful,
0:25:29.2 -> 0:25:31.475 although sometimes it is not as
0:25:31.475 -> 0:25:34.362 reliable as the scans and then also
0:25:34.362 -> 0:25:36.64 really listening to the patient.
0:25:36.64 -> 0:25:39.808 Patients can have symptoms that can be a
0:25:39.808 -> 0:25:42.82 tipoff that something is getting better
0:25:42.82 -> 0:25:45.52 or getting worse even before CAT
0:25:45.52 -> 0:25:48.109 Scan tell you what’s going on.
0:25:49.55 -> 0:25:52.292 And back to
0:25:52.292 -> 0:25:55.09 the story of my friend.
0:25:55.09 -> 0:25:58.12 She had chemotherapy as you suggested,
0:25:58.12 -> 0:26:01.138 and her tumor markers went down,
0:26:01.14 -> 0:26:02.472 which was great,
0:26:02.472 -> 0:26:05.58 but the imaging still showed that
0:26:05.672 -> 0:26:08.2 she had unresectable disease.
0:26:09.754 -> 0:26:14.093 She was quite happy to be done with
0:26:14.093 -> 0:26:18.223 chemo and really didn’t want to
0:26:18.23 -> 0:26:20.995 do much more, but was certainly
0:26:20.995 -> 0:26:22.74 interested in clinical trials.
0:26:22.74 -> 0:26:25.61 So let’s talk about clinical trials,
0:26:25.61 -> 0:26:27.086 both in that setting,
0:26:27.086 -> 0:26:29.3 after you don’t respond
0:26:29.368 -> 0:26:31.483 to standard chemotherapy as well
0:26:31.483 -> 0:26:33.598 as clinical trials that might
0:26:33.673 -> 0:26:35.788 be offered to patients upfront
0:26:35.788 -> 0:26:37.903 as new therapies are developed.
So what are you most excited about?

I think it’s interesting that you say that, I find that when I talk to a patient about a clinical trial sometimes they say to me, do you think I'm ready for a clinical trial?

As if it’s something that we wait until we don’t have other options, and clinical trials are important at every phase of someone’s disease, whether they are initially diagnosed or whether they have progressed on one or two prior therapies.

We are always trying to figure out what’s the best thing to do. And so the clinical trials that we are working on that we’re excited about, I think we are still trying to find a role for immunotherapy in pancreas cancer, the same as in other diseases like lung cancer or Melanoma.

But it’s been a challenge, and so we are doing clinical trials that are looking at immunotherapy combinations as opposed to just a single drug to see if it might be better and we’re looking at clinical trials that are trying to attack not just the tumor itself, but the scar tissue in the environment around the cancer cells.
One of the challenging things about pancreas cancer is that it almost builds this protective shell around itself that can potentially make it more difficult for our treatments to get in, and so looking at drugs that can potentially eat away at that might help our more standard therapies be more effective.

Doctor Jeremy Kortmansky is an associate professor of clinical medicine in medical oncology at the Yale School of Medicine. If you have questions, the address is canceranswers@yale.edu and past editions of the program are available in audio and written form at yalecancercenter.org. We hope you’ll join us next week to learn more about the fight against cancer here on Connecticut Public Radio.